keyword
MENU ▼
Read by QxMD icon Read
search

Liver chemoembolization

keyword
https://www.readbyqxmd.com/read/29145036/liver-immunotolerance-and-hepatocellular-carcinoma-patho-physiological-mechanisms-and-therapeutic-perspectives
#1
REVIEW
Gaël S Roth, Thomas Decaens
At the moment of the diagnosis of hepatocellular carcinoma (HCC), 70% of patients have only access to palliative treatments, with very few therapeutic options. Liver immunology is very specific, and liver immunotolerance is particularly developed because of the constant and massive influx of antigens. Deregulation of hepatic immunotolerance is implicated in chronic liver diseases development and particularly in liver carcinogenesis. For these reasons, HCC may be an excellent candidate for anticancer immunotherapies such as immune checkpoint inhibitors targeting CTLA-4 and PD-L1/PD-1...
November 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29137099/chemoembolization-for-hepatocellular-carcinoma-fed-by-right-internal-thoracic-artery
#2
Tao Shen, Zhongzhi Jia, Yuanquan Huang, Shaoqin Li, Guomin Jiang, Lihua Cheng
The purpose of the study was to evaluate the value of transarterial chemoembolization (TACE) via right internal thoracic artery (RITA) for patients with unresectable hepatocellular carcinoma (HCC).From January 2000 to June 2016, a retrospective study was conducted of all patients with unresectable HCC who underwent TACE via RITA across 3 medical centers. The technical success, serum alpha-fetoprotein (AFP) level changes, major complications, disease control rate, and survival were evaluated and analyzed.During the study peroid, in all, 21 patients (men 21; mean age 57...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29137051/neutrophil-to-lymphocyte-and-aspartate-to-alanine-aminotransferase-ratios-predict-hepatocellular-carcinoma-prognosis-after-transarterial-embolization
#3
Chang Liu, Bang-Sheng Jia, Bing-Wen Zou, Hua Du, Lu-Nan Yan, Jia-Yin Yang, Li Jiang, Tian-Fu Wen, Wu-Sheng Lu
The neutrophil-to-lymphocyte ratio (NLR) reflects the systematic inflammatory status, and the aspartate aminotransferase-to-alanine aminotransferase ratio (AAR) is a biomarker of liver fibrosis and cirrhosis. These values can be conveniently obtained from routine blood tests; however, their combined clinical utility has not been extensively studied in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). This study aimed to investigate the prognostic value of NLR-AAR in patients with unresectable HCC undergoing TACE...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29133753/transcatheter-arterial-chemoembolization-combined-with-simultaneous-computed-tomography-guided-radiofrequency-ablation-for-large-hepatocellular-carcinomas
#4
Tai-Yang Zuo, Feng-Yong Liu, Mao-Qiang Wang, Xian-Xian Chen
BACKGROUND: Currently, the treatment of large hepatocellular carcinoma (HCC) is still a challenging problem. Transcatheter arterial chemoembolization (TACE) is the main treatment for intermediate end-stage HCC, while it is only a palliative and not a curative treatment due to the existence of residual tumors, and radiofrequency ablation (RFA) has limitations in complete ablation of large HCC. We hypothesized that TACE combined with simultaneous RFA (herein referred to as TACE + RFA) could improve the efficacy and survival of large HCC...
November 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/29133751/shanghai-score-a-prognostic-and-adjuvant-treatment-evaluating-system-constructed-for-chinese-patients-with-hepatocellular-carcinoma-after-curative-resection
#5
Hui-Chuan Sun, Lu Xie, Xin-Rong Yang, Wei Li, Jian Yu, Xiao-Dong Zhu, Yong Xia, Ti Zhang, Yang Xu, Bo Hu, Li-Ping Du, Ling-Yao Zeng, Jian Ouyang, Wei Zhang, Tian-Qiang Song, Qiang Li, Ying-Hong Shi, Jian Zhou, Shuang-Jian Qiu, Qian Liu, Yi-Xue Li, Zhao-You Tang, Yu Shyr, Feng Shen, Jia Fan
BACKGROUND: For Chinese patients with hepatocellular carcinoma (HCC), surgical resection is the most important treatment to achieve long-term survival for patients with an early-stage tumor, and yet the prognosis after surgery is diverse. We aimed to construct a scoring system (Shanghai Score) for individualized prognosis estimation and adjuvant treatment evaluation. METHODS: A multivariate Cox proportional hazards model was constructed based on 4166 HCC patients undergoing resection during 2001-2008 at Zhongshan Hospital...
November 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/29116741/high-performance-plga-magnetic-microspheres-prepared-by-rotating-membrane-emulsification-for-transcatheter-arterial-embolization-and-magnetic-ablation-in-vx2-liver-tumors
#6
Yi-Jun Liang, Hui Yu, Guodong Feng, Linlin Zhuang, Wei Xi, Ming Ma, Jun Chen, Ning Gu, Yu Zhang
Interventional embolization is a popular minimally invasive vascular therapeutic technique and has been widely applied for hepatocellular carcinoma (HCC) therapy. However, harmful effects caused by transcatheter arterial chemoembolization (TACE) and radioembolization, such as the toxicity of chemotherapy or excessive radiation damage, are serious disadvantages and significantly reduce the therapeutic efficacy. Here, a synergistic therapeutic strategy combined transcatheter arterial embolization and magnetic ablation (TAEMA) by using PLGA-magnetic microspheres (MMs) has been successfully applied to orthotopic VX2 liver tumors of rabbits...
November 8, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29113660/functional-hepatic-imaging-as-a-biomarker-of-primary-and-secondary-tumor-response-to-loco-regional-therapies
#7
REVIEW
H L Lewis, M A Ghasabeh, P Khoshpouri, I R Kamel, T M Pawlik
Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29110217/aggressive-intrahepatic-therapies-for-synchronous-hepatocellular-carcinoma-with-pulmonary-metastasis
#8
Z Hu, P Huang, Z Zhou, W Li, J Xu, K Xu, J Wang, H Zhang
PURPOSE: Prognosis of synchronous hepatocellular carcinoma (HCC) patients with pulmonary metastasis (PM) was poor, while aggressive intrahepatic therapies remained controversial. This study aimed to investigate the significance of aggressive intrahepatic therapies for synchronous PM-HCC. METHODS: Synchronous PM-HCC patients were retrospectively enrolled from Sun Yat-sen Memorial Hospital of Sun Yat-sen University during January 2000 and December 2015. Univariate and multivariate analysis were performed to investigate the prognostic factors...
November 6, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29098752/hemobilia-immediately-after-transcatheter-arterial-chemoembolization-using-drug-eluting-beads-for-hepatocellular-carcinoma-with-intrahepatic-bile-duct-invasion
#9
Maiko Nishi, Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Takuro Hisanaga, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida
Transcatheter arterial chemoembolization (TACE) is used as a palliative treatment for unresectable hepatocellular carcinoma (HCC) worldwide. Recently, a novel drug delivery-embolic agent, the drug-eluting bead (DEB), was introduced for TACE. There are a few reports of tumor hemorrhage after TACE using DEB (DEB-TACE) for HCC. However, there have not been any reports of hemobilia immediately after DEB-TACE for an HCC with intrahepatic bile duct invasion. Here, the first such case is reported. A 71-year-old woman was admitted to our hospital to undergo DEB-TACE for multiple HCCs with worsening left intrahepatic bile duct dilatation...
November 2, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29097347/dual-balloon-infusion-microcatheter-for-selective-drug-eluting-bead-transarterial-chemoembolization-initial-feasibility-study
#10
Wayne L Monsky, Siddharth A Padia, Andrew Hal Hardy
PURPOSE: We aimed to demonstrate feasibility of the use of a dual-balloon infusion microcatheter for segmental/subsegmental drug-eluting bead transarterial chemoembolization (DEB-TACE). METHODS: Over a 16-month period, 15 segmental and 21 subsegmental DEB-TACE procedures were attempted using a dual-balloon anti-reflux microcatheter (IsoFlow™ microcatheter, Vascular Designs Inc.) in 21 patients (15 males; median age, 61 years; range, 49-82 years) with hepatocellular carcinoma (Barcelona clinic liver cancer stage A [n=4]; B [n=12]; C [n=5]) with one to three tumors, median size of 3...
November 2017: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/29095307/survival-benefit-of-radiofrequency-ablation-for-solitary-3-5%C3%A2-cm-hepatocellular-carcinoma-an-analysis-for-nationwide-cancer-registry
#11
COMPARATIVE STUDY
Seung Ho Lee, Young-Joo Jin, Jin-Woo Lee
We retrospectively compared overall survival (OS) and progression-free survival (PFS) of patients with single (3-5 cm) hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer (BCLC) stage A treated by surgical resection (SR), radiofrequency ablation (RFA), or transarterial chemoembolization (TACE).Of the 38,167 HCC patients registered between 2008 and 2010 at Korea Central Cancer Registry, National Cancer Center of South Korea, 13% patients were randomly abstracted, and 4596 patients could be analyzed...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29090997/safety-and-efficacy-outcomes-of-embolization-in-hepatic-sarcomas
#12
David B Pierce, Guy E Johnson, Eric Monroe, Elizabeth T Loggers, Robin L Jones, Seth M Pollack, Siddharth A Padia
OBJECTIVE: The outcome for patients with unresectable hepatic sarcoma is poor with a median survival period of 12-16 months. The purpose of this study was to evaluate liver-directed transcatheter therapies for the treatment of hepatic sarcomas. MATERIALS AND METHODS: In a retrospective study, the cases of patients with primary and metastatic hepatic sarcoma treated by transcatheter embolization, chemoembolization, and (90)Y radioembolization between 2004 and 2015 were identified...
November 1, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29090102/complete-remission-after-sequential-therapy-of-drug-eluting-beads-transarterial-chemoembolization-and-liver-resection-in-large-solitary-nodule-hepatocellular-carcinoma
#13
Juferdy Kurniawan, Andri Sanityoso Sulaiman, Sahat Basana Romanti Ezer Matondang, Toar Jean Maurice Lalisang, Ening Krisnuhoni, Steven Zulkifly
Hepatocellular carcinoma (HCC) is the fifth most prevalent and the second highest cause of death among cancer. The treatment of large solitary nodule HCC is still challenging. Transarterial chemoembolization (TACE) and liver resection are two modalities of therapy in HCC management. However, recurrence rate from each therapy is relatively high. We report a case of 46-year-old man diagnosed with large solitary nodule HCC, who was treated with drug eluting bead TACE (DEB-TACE) prior to liver resection. Studies about this combination are still limited and showed various results...
2017: Case Reports in Hepatology
https://www.readbyqxmd.com/read/29080006/local-arterial-therapies-in-the-management-of-unresectable-hepatocellular-carcinoma
#14
REVIEW
Samdeep K Mouli, Laura W Goff
Most patients with hepatocellular carcinoma present with intermediate to advanced disease, where curative therapies are no longer an option. These patients with intermediate to advanced disease represent a heterogeneous population with regard to tumor burden, liver function, and performance status. While the Barcelona Clinic Liver Cancer (BCLC) staging system offers guidelines for the management of these patients, strict adherence to these guidelines may limit treatment options for these patients. Several locoregional therapies exist for these patients, including conventional transarterial chemoembolization (cTACE), transarterial embolization (TAE), drug-eluting embolization (DEE), and radioembolization...
October 27, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29076939/transarterial-chemoembolization-for-hepatocellular-carcinoma-development-and-external-validation-of-the-munich-tace-score
#15
Mark Op den Winkel, Dorothea Nagel, Philip Op den Winkel, Jörg Trojan, Philipp M Paprottka, Christian J Steib, Laura Schmidt, Markus Göller, Petra Stieber, Peter Göhring, Andreas Herbst, Markus Rentsch, Enrico N De Toni, Burkhard Göke, Alexander L Gerbes, Frank T Kolligs
BACKGROUND: Allocation of patients with hepatocellular carcinoma (HCC) to the adequate therapy is determined by both tumor burden and liver function. The Barcelona Clinic Liver Cancer (BCLC) staging system and therapeutic algorithm recommends transarterial chemoembolization (TACE) based on the best evidence available to patients with intermediate-stage HCC (BCLC-B). However, many centers also treat subgroups of patients outside these recommendations and with more advanced disease by TACE...
October 25, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29074347/management-consensus-guideline-for-hepatocellular-carcinoma-2016-updated-by-the-taiwan-liver-cancer-association-and-the-gastroenterological-society-of-taiwan
#16
(no author information available yet)
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC. METHODS: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention...
October 23, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29072394/evaluation-on-efficacy-and-safety-of-arsenic-trioxide-plus-transcatheter-arterial-chemoembolization-versus-transcatheter-arterial-chemoembolization-alone-for-unresectable-primary-liver-cancer
#17
Haitao Yang, Sijing Zhou, Ruifen Shen, Shuimei Luo, Lina Li, Heng Lin, Huijuan Chen, Ziyuan Liao, Wanzun Lin, Xianhe Xie
Currently, some clinical trials of arsenic trioxide (As203) plus transcatheter arterial chemoembolization (TACE) in the treatment of unresectable primary liver cancer (PLC) had been conducted, but the results were controversial. Therefore, we performed a meta-analysis on 14 clinical trials (1076 cases) to evaluate efficacy and safety of As203 plus TACE versus TACE alone for unresectable PLC. The primary end points included objective response rate (ORR), karnofsky performance score (KPS) improvement rate, and 1-year survival rate...
October 26, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29067511/safety-and-efficacy-of-transarterial-radioembolization-combined-with-chemoembolization-for-bilobar-hepatocellular-carcinoma-a-single-center-retrospective-study
#18
Joon Ho Kwon, Gyoung Min Kim, Kichang Han, Jong Yun Won, Man Deuk Kim, Do Yun Lee, Junhyung Lee, Woosun Choi, Yong Seek Kim, Do Young Kim, Kwang-Hyub Han
BACKGROUND: Radioembolization induced liver disease (REILD) is a possible sequela of transarterial radioembolization (TARE), particularly in cases of whole-liver treatment. To mitigate this problem, the safety and efficacy of combined transarterial chemoembolization (TACE) and TARE were evaluated for patients with bilobar hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Nineteen patients (mean age 60 years; range 27-82 years) treated for HCC between June 2012 and September 2014 were included in the analysis...
October 24, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29066730/neutrophil-lymphocyte-ratio-plus-prognostic-nutritional-index-predicts-the-outcomes-of-patients-with-unresectable-hepatocellular-carcinoma-after-transarterial-chemoembolization
#19
Chang Liu, Lei Li, Wu-Sheng Lu, Hua Du, Lu-Nan Yan, Jia-Yin Yang, Tian-Fu Wen, Guo-Jun Zeng, Li Jiang, Jian Yang
For many malignancies, inflammation-based scores correlate with survival. The neutrophil-to-lymphocyte ratio (NLR) and prognostic nutritional index (PNI) are immunonutritional indices associated with postoperative outcomes in patients with hepatocellular carcinoma (HCC). We evaluated whether a combined preoperative NLR and PNI score was prognostically superior to either index alone in 793 patients with unresectable HCC after transarterial chemoembolization. Patient demographic, clinical, and pathological data were also collected and analysed...
October 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29066120/stereotactic-body-radiation-therapy-as-an-alternative-to-transarterial-chemoembolization-for-hepatocellular-carcinoma
#20
Eli Sapir, Yebin Tao, Matthew J Schipper, Latifa Bazzi, Paula M Novelli, Pauline Devlin, Dawn Owen, Kyle C Cuneo, Theodore S Lawrence, Neehar D Parikh, Mary Feng
PURPOSE: To conduct a large single-institution comparison of transarterial chemoembolization (TACE) and stereotactic body radiation therapy (SBRT) outcomes in similar groups of patients with hepatocellular carcinoma (HCC). METHODS AND MATERIALS: From 2006 to 2014, 209 patients with 1 to 2 tumors underwent TACE (n=84) to 114 tumors or image guided SBRT (n=125) to 173 tumors. Propensity score analysis with inverse probability of treatment weighting was used to compare outcomes between treatments while adjusting for imbalances in treatment assignment...
September 14, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
72036
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"